Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42206633
Type of treatment:
Diseases:
Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)
Short title:
Primary objective:
Key inclusion criteria:
Patiens 18-60 years old who receive allo-tx in AL Amyloidosis. Eligible Patients in follow up are alseo welcome.
Country:
Principal investigator:
Stefan Schonland
EBMT Study coordinator:
Jennifer Hoek